We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The trial did not reach a two-step or greater ...

Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 ...

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4) inhibitors in ...

Starting intravitreous aflibercept (Eylea, Regeneron) among patients with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema did not lead to better visual ...

Non-proliferative diabetic retinopathy is the earliest stage of this diabetes complication. You may not have symptoms, and medical treatments may not be needed aside from diabetes management. As ...

The risk for DR progression was lower among individuals who initiated empagliflozin vs those who began DPP4i therapy. (HealthDay News) — Empagliflozin initiation is not associated with incident ...

Findings of the PANORAMA randomized clinical trial show that when patients with severe nonproliferative diabetic retinopathy were treated with intravitreal aflibercept, severity improved over 100 ...

SAN FRANCISCO -- Treatment with a novel antibody biopolymer conjugate (ABC) targeting VEGF led to favorable outcomes for patients with diabetic retinopathy (DR) in a large randomized trial. Results ...

Antiplatelet/anticoagulant (APAC) therapy can protect patients from developing nonproliferative diabetic retinopathy, according to a recent study. Patients with ...

Proliferative diabetic retinopathy and non-proliferative diabetic retinopathy are stages of diabetic retinopathy. The former is the more severe form that can lead to vision loss. Unmanaged diabetes ...